Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.
Percutaneous aortic valve replacement is an emerging alternative for high surgical risk patients with native aortic valve stenosis. We describe for the first time a valve-in-valve procedure with a CoreValve prosthesis for the treatment of a severely stenotic degenerated aortic bioprosthesis.
Giannini
Cristina
C
Cardiology Unit, Cardiothoracic and Vascular Department, University of Pisa, Pisa, Italy. crigiannini@hotmail.it
De Carlo
Marco
M
Guarracino
Fabio
F
Donne
Maria G D
MG
Benedetti
Giovanni
G
Verunelli
Francesco
F
Petronio
Anna S
AS
D000369:Aged, 80 and over; D001021:Aortic Valve / Q000473:pathology / Q000601:surgery; D001024:Aortic Valve Stenosis / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D001241:Aspirin / Q000008:administration & dosage; D002114:Calcinosis / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D004452:Echocardiography; D017548:Echocardiography, Transesophageal; D005260:Female; D005500:Follow-Up Studies; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011475:Prosthesis Failure; D012307:Risk Factors; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin